492 related articles for article (PubMed ID: 20100483)
1. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
2. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
3. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
4. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
6. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
7. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
8. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
9. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Santamariña M; Hernández G; Zalvide J
Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.
Zhang J; Xu K; Liu P; Geng Y; Wang B; Gan W; Guo J; Wu F; Chin YR; Berrios C; Lien EC; Toker A; DeCaprio JA; Sicinski P; Wei W
Mol Cell; 2016 Jun; 62(6):929-942. PubMed ID: 27237051
[TBL] [Abstract][Full Text] [Related]
12. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
13. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
14. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
15. Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.
Hirai H; Shimomura T; Kobayashi M; Eguchi T; Taniguchi E; Fukasawa K; Machida T; Oki H; Arai T; Ichikawa K; Hasako S; Haze K; Kodera T; Kawanishi N; Takahashi-Suziki I; Nakatsuru Y; Kotani H; Iwasawa Y
Cell Cycle; 2010 Apr; 9(8):1590-600. PubMed ID: 20372067
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Fry DW; Harvey PJ; Keller PR; Elliott WL; Meade M; Trachet E; Albassam M; Zheng X; Leopold WR; Pryer NK; Toogood PL
Mol Cancer Ther; 2004 Nov; 3(11):1427-38. PubMed ID: 15542782
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
[TBL] [Abstract][Full Text] [Related]
20. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
